Genor Biopharma Holdings (HKSE:06998) EPS (Diluted) : HK$-1.46 (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings EPS (Diluted)?

Genor Biopharma Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-0.86. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.46.

Genor Biopharma Holdings's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.86. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.46.

Genor Biopharma Holdings's EPS without NRI for the six months ended in Dec. 2023 was HK$-0.86. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.46.

During the past 3 years, the average EPS without NRIGrowth Rate was 53.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was -8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Genor Biopharma Holdings's highest 3-Year average EPS without NRI Growth Rate was 53.90% per year. The lowest was -47.40% per year. And the median was -10.30% per year.

Genor Biopharma Holdings EPS (Diluted) Historical Data

The historical data trend for Genor Biopharma Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings EPS (Diluted) Chart

Genor Biopharma Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-1.21

-14.65

-2.17

-1.62

-1.46

Genor Biopharma Holdings Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial					-1.16	-0.96	-0.72	-0.59	-0.86

Competitive Comparison of Genor Biopharma Holdings's EPS (Diluted)

For the Biotechnology subindustry, Genor Biopharma Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genor Biopharma Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's PE Ratio falls into.

Genor Biopharma Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Genor Biopharma Holdings's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-737.603	-	0)	/	506.245
	=	-1.46

Genor Biopharma Holdings's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-437.304	-	0)	/	506.737
	=	-0.86

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.46

Genor Biopharma Holdings (HKSE:06998) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Genor Biopharma Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings (HKSE:06998) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

67N0:Germany

Address

1690 Zhangheng Road, Building 3, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL mAb drug candidate.

Executives

Hillhouse Investment Management, Ltd.	2102 Investment manager
Hhjh Holdings Limited	2101 Beneficial owner
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hh Bio Investment Fund, L.p.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager
Hh Bio Investment Fund L.p.	2201 Interest of corporation controlled by you
Temasek Capital (private) Limited
Aranda Investments Pte. Ltd.
Seletar Investments Pte Ltd
Walga Biotechnology Limited	2101 Beneficial owner
Shang Hai Wo Jia Sheng Wu Ji Shu You Xian Gong Si	2201 Interest of corporation controlled by you
Yun Nan Wo Sen Sheng Wu Ji Shu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited

Genor Biopharma Holdings (HKSE:06998) Headlines

No Headlines